Trial is approved for stem cell treatment for dry AMD

02/3/2012 | Wall Street Journal, The

The FDA is permitting StemCells to conduct a safety and efficacy trial of therapeutic candidate HuCNS-SC cells among patients with dry age-related macular degeneration, or AMD. Last year, testing of the adult stem cell treatment for a rare childhood brain disorder was halted because of a lack of qualified participants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI